Communiqués Takeda Pharmaceutical Company Limited Boerse Muenchen

Actions

TKDA

US8740602052

Produits pharmaceutiques

Temps réel Boerse Muenchen 07:31:00 09/09/2026			Varia. 5j.	Varia. 1 janv.
15,80 ^EUR	0,00%		+3,23%	+22,14%

08/09	Le traitement de Pharvaris contre une maladie génétique atteint son objectif principal en phase finale d'essai	RE
04/09	Takeda Pharmaceutical : un dirigeant cède des actions pour un montant de 2 148 372 dollars, selon un récent document de la SEC	MT

Communiqués

31/08	Takeda Receives U.S. FDA Approval of MIMRYLO, Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera	AQ
29/08	Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera	BU
24/08	Takeda Pharmaceutical : Provides Update on ADZYNMA (ADAMTS13, recombinant-krhn)	PU
24/08	ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1	BU
06/08	U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1	BU
30/07	Takeda Pharmaceutical : Earnings Report（Kessan Tanshin）Earnings Report（Kessan Tanshin）Download Earnings Report（Kessan Tanshin） (qr2026 q1 er en)	PU
30/07	Takeda Announces FY2026 First Quarter Results, Near-Term Launch Preparations and Pipeline Progress on Track	BU
23/07	Takeda Pharmaceutical : ORZEYFUL (oveporexton) Approved in China as First Orexin Agonist and Only Medicine to Treat Narcolepsy Type 1	PU
17/07	Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies	BU
16/07	Takeda Pharmaceutical : to Hold Earnings Call for Fiscal Year 2026 1st Quarter on July 30	PU
13/07	Takeda and the Indonesian Government Announce Landmark Collaboration to Strengthen Healthcare Resilience and Expand Access to Lifesaving Plasma-Derived Medicinal Products	BU
09/07	Takeda Pharmaceutical : Filing of Corporate Governance Report to the Tokyo Stock Exchange	PU
08/07	Takeda Pharmaceutical : Completed Issuance of New Shares and Disposal of Treasury Shares under the Long-Term Incentive Plan for Company Group Employees Outside of Japan with Partial Forfeiture of Rights Granted to Allottees	PU
24/06	Takeda Pharmaceutical : Integrated Report (AIR 2026 EN)	PU
24/06	Takeda Announces New Assignments of Directors and Appointment of Julie Kim as Representative Director, President and CEO	BU
15/06	New Pivotal Study Data Show Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 1	BU
11/06	Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations	BU
09/06	U.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO® (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease	BU
09/06	Takeda Pharmaceutical : Notice Concerning Issuance of New Shares and Disposal of Treasury Shares under the Long-Term Incentive Plan for Company Group Employees Outside of Japan	PU
05/06	Takeda Pharmaceutical : Updates FY2025 Financial Results Based on Impact of AMITIZA® Antitrust Verdict	PU
01/06	Takeda Pharmaceutical : Notice Concerning Withdrawal of Shelf Registration Statement and Filing of New Shelf Registration Statement in Japan	PU
19/05	Takeda Pharmaceutical Company Limited: Takeda Provides an Update regarding Jury Verdict in AMITIZA® (lubiprostone) Antitrust Litigation in the U.S. and Related Revision to FY2025 Financial Results	EQ
19/05	Takeda Pharmaceutical : Provides an Update regarding Jury Verdict in AMITIZA® (lubiprostone) Antitrust Litigation in the U.S. and Related Revision to FY2025 Financial Results	PU
18/05	Attorneys at Hagens Berman Announce $474M Win in Amitiza Jury Trial Against Takeda	BU
16/05	Pharmaceutical company Takeda announces sweeping cutbacks; impact on Belgian division unclear	AQ